Core Molding Technologies (AMEX:CMT) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.14 by 307.14 percent. This is a 1040 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $86.40 million which beat the analyst consensus estimate of $77.60 million by 11.34 percent. This is a 18.08 percent increase over sales of $73.17 million the same period last year.
Atyr Pharma’s Efzofitimod Has Received FDA For Systemic Sclerosis (SSc) And Fast Track Designation For SSc-Associated Interstitial Lung Disease (SSc-ILD); Proof-of-concept Study In SSc-ILD Expected To Begin In 2023
The Phase 2 study is expected to be a randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety and tolerability of efzofitimod in patients with SSc-ILD. This is expected to be
